rfk glp-1 Jr. considering 'framework' for Medicaid, Medicare coverage of GLP-1s RFK Jr., Dr. Oz set

Additionally, critical factors that shape the relationship between GLP-1RAs and cancer risk are thoroughly analyzed, including patient demographics, comorbidities, treatment regimens, and lifestyle factors, offering essential insights for developing individualized treatment protocols

Only 40% of 2023 initiators remained on therapy after a year compared to 34% of 2022 initiators and 33% of 2021 initiators

Over time, lower intake can make it more difficult to get enough protein, fluids, and essential nutrients

-Rich in fiber: The FDA qualifies this as "high" or an "excellent source," and means it contains at least 20% or more of the Daily Value

Orforglipron is an emerging oral small-molecule GLP-1 receptor agonist that offers glucose-lowering and weight-loss without injections